NCT07728448Not yet recruiting
Predictors of Pulmonary Embolism in Interstitial Lung Disease With Worsening Symptoms
Predictors of Pulmonary Embolism in Patients With Interstitial Lung Diseases Presenting With Worsening Respiratory Symptoms
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
People with interstitial lung disease (ILD) can sometimes experience a sudden and severe worsening of their breathing. While this can be caused by a flare-up of the lung disease itself, it can also be caused by a blood clot in the lungs, known as a pulmonary embolism (PE). It is often difficult for doctors to tell the difference between these two emergencies because their symptoms, such as shortness of breath and low oxygen levels, are very similar. Traditional scoring systems used to predict blood clots are often less accurate for patients who already have chronic lung diseases like ILD. The main goal of this observational study is to find better, more reliable ways to predict which ILD patients with worsening breathing symptoms actually have a pulmonary embolism. Researchers will observe 70 adult patients with ILD who come to the hospital with a sudden worsening of their symptoms (such as shortness of breath, chest pain, or low oxygen) and who require a specific type of CT scan (Computed Tomography Pulmonary Angiography, or CTPA) as part of their standard medical care to check for blood clots. The study will compare the patients whose CT scan confirms a blood clot to those whose scan does not show a clot. By comparing these two groups, the research team will evaluate various clinical signs, routine blood tests, novel inflammatory markers, and heart/lung imaging details. Identifying strong predictors of pulmonary embolism in this specific group of patients could help doctors diagnose lung blood clots faster and more accurately, leading to better clinical decision-making and improved patient outcomes
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 22 Jul 2026
- Start date
- Aug 2026
- Primary completion date
- Aug 2027
- Lead sponsor
- Assiut University
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT07728448
What you commit to
- Study type: Observational
- Planned participants: 70
- From Aug 2026 to the primary completion date, Aug 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously diagnosed acute pulmonary embolism receiving anticoagulant therapy
- Acute myocardial infarction or ischemic stroke within the previous month
- Major surgery or trauma within four weeks
Other illness
- Active malignancy
- Severe renal impairment contraindicating contrast-enhanced CTPA
Age
- Age \< 18 years
Other
- Pregnancy
- Known inherited or acquired thrombophilia
Who the study is looking for
- Age ≥ 18 years
- Confirmed diagnosis of ILD based on multidisciplinary discussion and HRCT findings, with or without histopathological confirmation
- Acute unexplained worsening of dyspnea, hypoxemia, chest pain, syncope, or clinical suspicion of PE
- Undergoing CTPA as part of routine clinical management
- Provision of informed consent
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.